Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.
Read Full NewsALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Why patients with IgA nephropathy want to understand their disease, not just follow instructions.
Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.
Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.
Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.
1.
Women are more susceptible to the stress caused by inflation.
2.
Pancreatic cancer RNA vaccine shows durable T cell immunity
3.
In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events
4.
Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy
5.
C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.
1.
Unlocking the Potential of Plinabulin: A New Frontier in Cancer Treatment
2.
A Closer Look at Breast Cancer: Examining the Ultrasound Images
3.
Rehabilitation After Function-Preserving Oncologic Reconstruction
4.
Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact
5.
Transformative Methods in Hematology for Better Care
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
5.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge